Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRINASDAQ:BXRXNASDAQ:CINGNASDAQ:CMRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.78-3.2%$1.01$0.65▼$2.43$6.88M0.3909,092 shs5,204 shsBXRXBaudax Bio$0.02+7.4%$0.02$0.01▼$3.47$1.14M1.57281,029 shs310,800 shsCINGCingulate$4.10-1.6%$4.24$1.80▼$20.83$13.15M-0.83134,912 shs36,081 shsCMRAComera Life Sciences$0.00$0.00$0.00▼$0.06$6K0.798,033 shsN/A20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera+0.25%-9.49%-7.93%-26.51%-53.97%BXRXBaudax Bio0.00%0.00%0.00%0.00%0.00%CINGCingulate-2.12%+0.48%+5.32%-18.43%+288.79%CMRAComera Life Sciences0.00%0.00%0.00%0.00%-99.41%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRIBiofrontera1.9588 of 5 stars3.53.00.00.00.60.01.3BXRXBaudax BioN/AN/AN/AN/AN/AN/AN/AN/ACINGCingulate3.2431 of 5 stars3.65.00.00.02.51.70.6CMRAComera Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera 3.00Buy$7.00803.23% UpsideBXRXBaudax Bio 0.00N/AN/AN/ACINGCingulate 3.25Buy$16.00290.72% UpsideCMRAComera Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CING, BXRX, BFRI, and CMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2025CINGCingulateHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.001/30/2025CINGCingulateHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $20.001/10/2025CINGCingulateRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/10/2025CINGCingulateRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$37.32M0.18N/AN/A$3.16 per share0.25BXRXBaudax Bio$1.27M0.90N/AN/A($14.93) per share0.00CINGCingulateN/AN/AN/AN/A($70.63) per shareN/ACMRAComera Life Sciences$1.00M0.01N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$20.13M-$2.26N/AN/AN/A-36.31%-565.73%-96.64%5/13/2025 (Estimated)BXRXBaudax Bio-$58.79M-$9.23N/AN/AN/AN/AN/A-175.11%N/ACINGCingulate-$23.53M-$14.64N/AN/AN/AN/A-570.20%-236.15%4/7/2025 (Estimated)CMRAComera Life Sciences-$18MN/A0.00∞N/AN/AN/AN/AN/ALatest CING, BXRX, BFRI, and CMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/7/2025N/ACINGCingulate-$1.48N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/ABXRXBaudax BioN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/ACMRAComera Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofronteraN/A1.530.94BXRXBaudax BioN/A0.070.07CINGCingulateN/A7.357.35CMRAComera Life SciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%BXRXBaudax Bio9.05%CINGCingulate41.31%CMRAComera Life SciencesN/AInsider OwnershipCompanyInsider OwnershipBFRIBiofrontera0.21%BXRXBaudax Bio0.10%CINGCingulate17.06%CMRAComera Life Sciences8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera708.87 million7.73 millionNo DataBXRXBaudax Bio952.46 million52.41 millionNot OptionableCINGCingulate203.21 million2.66 millionNot OptionableCMRAComera Life Sciences230.74 million28.00 millionNot OptionableCING, BXRX, BFRI, and CMRA HeadlinesRecent News About These CompaniesTandy Leather Factory (NASDAQ:TLF) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comCarisma Therapeutics to Join Citizens JMP Life Sciences ConferenceMay 13, 2024 | msn.comComera Life Sciences Announces Sweeping Workforce TerminationJanuary 31, 2024 | msn.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionJanuary 4, 2024 | finance.yahoo.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionJanuary 4, 2024 | finance.yahoo.comComera Life Sciences to explore strategic alternativesDecember 6, 2023 | msn.comComera Life Sciences Announces Process Exploring Strategic AlternativesDecember 6, 2023 | finance.yahoo.comComera Life Sciences Stock (NASDAQ:CMRA), Analyst Ratings, Price Targets, PredictionsNovember 26, 2023 | benzinga.comComera Life Sciences Holdings Inc [CMRA] stock for 1,049,897 USD was acquired by Cherington CharlesNovember 18, 2023 | knoxdaily.comComera Life Sciences Designates Dorothy Clarke to Board of DirectorsNovember 14, 2023 | finance.yahoo.comComera Life Sciences Appoints Dorothy Clarke to Board of DirectorsNovember 13, 2023 | finance.yahoo.comComera Life Sciences GAAP EPS of -$0.10, revenue of $0.14MNovember 9, 2023 | msn.comComera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business HighlightsNovember 9, 2023 | finance.yahoo.comComera Life Sciences Holdings Inc [CMRA] Insider Activity: An Update for InvestorsNovember 8, 2023 | knoxdaily.comInvesting in Comera Life Sciences Holdings Inc (CMRA): What You Must KnowOctober 18, 2023 | knoxdaily.comComera Life Sciences Advancing Subcutaneous Monoclonal Antibody FormulationsOctober 18, 2023 | finance.yahoo.comComera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery ConferenceOctober 16, 2023 | finance.yahoo.comComera Life Sciences Holdings Inc [CMRA] 10% Owner makes an insider purchase of 2,053,789 shares worth 1.05 million.October 13, 2023 | knoxdaily.comMassive Insider Trade At Comera Life SciencesSeptember 13, 2023 | benzinga.com10% Owner At This Health Care Company Buys $1.05M of StockSeptember 12, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIs BigBear.ai's 25% Plunge a False Alarm or Fire Sale?By Jeffrey Neal Johnson | March 7, 2025View Is BigBear.ai's 25% Plunge a False Alarm or Fire Sale?4 EV Stocks Facing Uncertainty—Which Ones Will Survive?By Thomas Hughes | March 7, 2025View 4 EV Stocks Facing Uncertainty—Which Ones Will Survive?Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?By Chris Markoch | March 21, 2025View Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?D-Wave Quantum Stock Jumps on "Quantum Supremacy" NewsBy Chris Markoch | March 14, 2025View D-Wave Quantum Stock Jumps on "Quantum Supremacy" NewsAbbVie Stock Boosts Portfolios With Entry Into Weight Loss MarketBy Chris Markoch | March 23, 2025View AbbVie Stock Boosts Portfolios With Entry Into Weight Loss MarketCING, BXRX, BFRI, and CMRA Company DescriptionsBiofrontera NASDAQ:BFRI$0.78 -0.03 (-3.25%) As of 10:24 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Baudax Bio NASDAQ:BXRXBaudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.Cingulate NASDAQ:CING$4.10 -0.07 (-1.56%) As of 10:24 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Comera Life Sciences NASDAQ:CMRA$0.0002 0.00 (0.00%) As of 04/1/2025Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Reasons Why Halliburton is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
